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ABSTRACT 
 
Background: Despite FDA warnings that atypical antipsychotic medications are associated with an 
increased risk of death when used to treat behavioral disorders in older adults with dementia, they are 
prescribed to nearly one-third of older U.S. nursing home (NH) residents. Reasons for their high use in 
NHs are poorly understood, but may include pharmaceutical marketing efforts in the NH setting.  
 
Methods: This study is nested within an ongoing cluster randomized trial to improve the use of atypical 
antipsychotics in NHs. We analyzed semistructured interviews (n = 36) and surveys (n = 139) of 
administrators, directors of nursing and medical directors from 62 NHs in Connecticut. Using 
prescription drug claims from a national long-term care pharmacy, we arrayed study NHs into lowest to 
highest tertile of atypical antipsychotic use. We tested for differences in the receipt of information or 
clinical tools from pharmaceutical company representatives (PCRs) to manage dementia-related 
behaviors by medication use tertiles, adjusting for NH profit status, size, quality (overall, health 
inspections, staffing) and staffing measures (daily nurse hours per resident).  
 
Results: Average baseline use of atypical antipsychotics ranged from 6.6 to 44.3 percent of all residents 
in the facility. Approximately one-quarter of NH leaders presently receive information on dementia-
related behavioral management strategies from PCRs through detailing, in-service training, written or 
Web-based material or sponsorship as speakers. However, we did not detect statistically significant 
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differences in the receipt of information by level of atypical antipsychotic use, NH characteristics, quality 
and staffing measures.  
 
Conclusions: This first attempt to characterize pharmaceutical marketing within the NH setting did not 
find differences among reports of marketing efforts with respect to medication use and facility-level 
characteristics. However, studies across a wider geographic area should continue investigating the 
possible role of marketing efforts on overall use and choice of atypical antipsychotics in the NH setting.   
